Abstracts

The aim of this study was to verifying the usefulness of noninvasive indicator test (Neurocheck[trade]) to predict hypohidrosis and hypohidrosis-related symptoms in newly diagnosed pediatric epileptic patients with topiramate., A total of 46 epileptic patients (22 boys and 24 girls) with topiramate were evaluated in this study at the Department of Pediatrics, Chonbuk National University Hospital. We have measured sweating functions using a noninvasive sweating test (Neurocheck[trade]) before and 3 months later after topiramate initiation. We also made a direct survey for the hypohidrosis and hypohidrosis-related symptoms during topiramate treatment., The mean age was 7.8[plusmn]3.2. The mean dosage of topiramate was 4.5[plusmn]0.8mg/kg/day. Among the 46 epileptic patients, 17 patients (37.0%) experienced hypohidrosis and hypohidrosis-related symptoms on survey: 12 (26.1%) have facial flushing, 4 (8.7%) heat intolerance, 1 (2.2%) lethargy, but no one have anhidrosis. Among the 17 patients, 13 patients showed delayed sweat test after medication. Sixteen out of 46 patients (34.8%) showed delayed sweat function test by Neurocheck[trade] after medication. Thirteen out of these 16 patients had hypohydrosis-related symptoms. The overall measures of agreement between Neurocheck[trade] and the survey was 76.5%., The main result indicates that Neurocheck[trade] could be a useful test to detect and predict the topiramate induced hypohidrosis in pediatric epileptic patients. We recommend that patients who show the delayed, particularly delayed over 3 minutes, in Neurocheck[trade] test after topiramate initiation should be aware the hypohidrosis and hypohidrosis-related symptoms.,